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Stroke is the third leading cause of death in the US and the primary cause 
of long-term disability.  Acute ischemic stroke, the most common form of 
stroke, is caused by clotting in the cerebral arteries leading to brain oxygen 
deprivation and cerebral infarction. The events involved in stroke include 
brain cell injury or death, breakdown of the blood-brain barrier (BBB), 
edema, and hemorrhage, which are associated with the expression and 
activation of matrix metalloproteinases (MMPs), particularly MMP-9. In two 
focal cerebral ischemia paradigms – the filament-induced transient middle 
cerebral artery occlusion (MCAo) and the embolus-induced permanent 
MCAo in mice, we examined MMP-9 proteolysis of extracellular matrix 
(ECM) components and the neuroprotective effects of the highly selective 
mechanism-based inhibitor of MMP-9, SB-3CT, which is activated by 
MMP-9 under pathological conditions. We demonstrated that MMP-9 
degrades the ECM protein laminin and that this degradation induces 
neuronal apoptosis in a transient focal cerebral ischemia model in mice. 
SB-3CT dramatically blocks MMP-9 activity and decreases 
MMP-9-mediated laminin cleavage, thus rescuing neurons from apoptosis 
and ameliorating neurobehavioral outcomes. Significant therapeutic activity 
of SB-3CT is seen up to 6 h after initial brain damage. Moreover, treatment 
with SB-3CT attenuates brain MMP-9 activity and protects against delayed 
neuronal cell death in the embolus-induced permanent MCAo in mice. We 
conclude that MMP-9 is a highly promising drug target and that SB-3CT 
has significant therapeutic potential in stroke patients. 
 
